BioNTech gains rights to 4SC Discovery's potential cancer drugs

12/18/2012 | Genetic Engineering & Biotechnology News

4SC Discovery granted Germany-based BioNTech exclusive rights to market and commercialize its early-stage small molecule toll-like receptor agonists as immunotherapies for cancer. The research and licensing deal entitles 4SC to about $3.3 million upfront plus milestone and royalties. "Our goal is now to speed up and jointly develop a novel breakthrough therapy toward the market addressing the high medical need in the exciting field of cancer immunotherapy," 4SC Discovery Managing Director Daniel Vitt said.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Litigation
Center for Science in the Public Interest
Washington, DC
Health Plan CEO - Oregon
Trillium Community Health Plan
Eugene, OR
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Columbus, OH
Associate General Counsel
Patient-Centered Outcomes Research Institute
Washington, D.C , DC